Reporter brief
Senolytic drugs dasatinib plus quercetin reduced pro-inflammatory cells in small open-label IPF pilot study.
What happened
Open-label pilot study in patients with idiopathic pulmonary fibrosis examining intermittent oral dosing of dasatinib plus quercetin over 3 weeks. The intervention aimed to reduce pro-inflammatory cells and cellular senescence markers. The study assessed safety, tolerability, and effects on inflammatory biomarkers, with hypothesized preservation of functional outcomes.
Why it matters
Assessment pending; this report does not establish a change in evidence.
What it does NOT prove
- Limitations have not been recorded; consult the primary source.
Study design and sample
Rct; Human.
Patients with idiopathic pulmonary fibrosis (IPF)
- Design
- Rct
- Sample
- —
- Journal
- Wake Forest University Health Sciences
- Published
- May 12, 2020
Effect size
Not recorded.
Caveats
- Assessment: Pending.
- Only the source material recorded on this evidence page was assessed.
Conflicts and funding
Not recorded.
Previous evidence
See the Senolytics timeline and recorded assessment for prior evidence.
Primary source
Cancel Death charts and briefs may be reproduced editorially with attribution to CancelDeath.com. This brief is generated from the primary recorded source facts and assessment. Its review status is shown below; verify quotations against the paper before publication.